- CEO
- Fu Min Wang
- Full Time Employees
- 690
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Fuxin China
- IPO Date
- Aug 3, 2023
- Business
- Kingchem (Liaoning) Life Science Co., Ltd. is a contract development and manufacturing organization (CDMO) that provides customized chemical synthesis, process development, and commercial-scale manufacturing solutions for the global life sciences, pharmaceutical, agrochemical, and specialty chemical industries. The company specializes in advanced fluorine chemistry and hazardous reaction processing, delivering research, development, and production services across the lifecycle of small molecule therapeutics. Its core offerings and product lines include pharmaceutical intermediates and building blocks, such as fluorinated aromatics, fluorinated heterocycles, trifluoromethyl and difluoromethyl derivatives, chiral intermediates, and advanced active pharmaceutical ingredient (API) precursors; agrochemical fine chemicals and active intermediates for fungicides, herbicides, and insecticides; specialty electronic chemicals and fluorinated functional materials for high-technology applications; custom synthesis and contract manufacturing services, encompassing chemical route design, process optimization, safety assessment, scale-up synthesis, and both non-GMP and cGMP-compliant commercial production; and specialized technical engineering services, including continuous flow micro-reaction technology, cryogenic reactions, high-pressure hydrogenation, and hazardous fluorination reactions. The company serves global innovator pharmaceutical companies, multinational agrochemical enterprises, and biotechnology firms across China, North America, Europe, and the Asia-Pacific region. Founded in 2009 and headquartered in Fuxin, Liaoning Province, China, Kingchem (Liaoning) Life Science Co., Ltd. operates primary manufacturing facilities in Fuxin, research and technical support facilities in Dalian, and international customer service and commercialization networks through overseas affiliates in the United States. In recent developments, the company completed its initial public offering on the ChiNext board of the Shenzhen Stock Exchange (SZSE: 301509) in August 2023 to fund large-scale manufacturing expansion and technical capability upgrades. Operationally, the company has expanded its multi-purpose cGMP production lines and advanced fluorochemical continuous-flow engineering capacity at its Fuxin manufacturing hub, broadened strategic supply collaborations with global top-tier innovator pharmaceutical and crop protection clients, and enhanced its high-potency compound handling and green chemistry process optimization platforms to support commercial-scale pipeline projects.